Aristeia Capital L.L.C. Buys New Holdings in Tenet Healthcare Corporation $THC

Aristeia Capital L.L.C. bought a new stake in shares of Tenet Healthcare Corporation (NYSE:THC) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,841 shares of the company’s stock, valued at approximately $763,000.

Several other institutional investors also recently bought and sold shares of THC. Norges Bank purchased a new stake in Tenet Healthcare during the 4th quarter valued at about $248,494,000. Eminence Capital LP purchased a new stake in Tenet Healthcare during the 3rd quarter valued at about $225,263,000. Boston Partners boosted its holdings in Tenet Healthcare by 38.8% during the 3rd quarter. Boston Partners now owns 3,147,555 shares of the company’s stock valued at $638,958,000 after acquiring an additional 880,413 shares during the period. AQR Capital Management LLC boosted its holdings in Tenet Healthcare by 62.3% during the 3rd quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock valued at $380,989,000 after acquiring an additional 720,160 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in Tenet Healthcare by 375.7% during the 2nd quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock valued at $139,085,000 after acquiring an additional 624,125 shares during the period. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Tenet Healthcare Stock Down 2.7%

Shares of NYSE:THC opened at $178.63 on Thursday. Tenet Healthcare Corporation has a 52-week low of $146.60 and a 52-week high of $247.21. The firm has a market capitalization of $15.39 billion, a P/E ratio of 9.29, a P/E/G ratio of 1.51 and a beta of 1.28. The stock has a 50 day moving average price of $183.44 and a 200-day moving average price of $199.04. The company has a debt-to-equity ratio of 1.96, a quick ratio of 1.30 and a current ratio of 1.36.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, April 30th. The company reported $4.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The firm had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.39 billion. During the same quarter in the prior year, the company earned $4.36 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, equities research analysts anticipate that Tenet Healthcare Corporation will post 17.61 EPS for the current fiscal year.

Insider Buying and Selling

In other Tenet Healthcare news, Director Nadja West sold 3,000 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the sale, the director directly owned 24,805 shares in the company, valued at approximately $4,399,166.75. This trade represents a 10.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director J Robert Kerrey sold 5,638 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $174.52, for a total value of $983,943.76. Following the sale, the director owned 16,804 shares in the company, valued at approximately $2,932,634.08. This represents a 25.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.97% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Wall Street Zen lowered Tenet Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 11th. Wells Fargo & Company lowered their price target on Tenet Healthcare from $265.00 to $213.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Stephens lowered their price target on Tenet Healthcare from $275.00 to $260.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Leerink Partners upped their price target on Tenet Healthcare from $255.00 to $264.00 and gave the company an “outperform” rating in a research report on Friday, February 20th. Finally, Guggenheim lowered their price target on Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Eighteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Tenet Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $244.16.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.